title: Cerebral melanoma metastases: a critical review on diagnostic methods and therapeutic options.
abstract: Malignant melanoma represents the third most common cause for cerebral metastases after breast and lung cancer. Central nervous system (CNS) metastases occur in 10 to 40% of patients with melanoma. Most of the symptoms of CNS melanoma metastases are unspecific and depend on localization of the lesion. All patients with new neurological signs and a previous primary melanoma lesion must be investigated. Although primary diagnosis may rely on computed tomography scan, magnetic resonance images are usually used in order to study more precisely the characteristics of the lesions in and to embase the surgical plan. Other possible complementary exams are: positron emission tomography, iofetamine cintilography, immunohistochemistry of liquor, monoclonal antibody immunocytology, optical coherence tomography, and transcriptase-polymerase chain reaction. Treatment procedures are indicated based on patient clinical status, presence of unique or multiple lesions, and family agreement. Often surgery, radiosurgery, whole brain radiotherapy, and chemotherapy are combined in order to obtain longer remissions and optimal symptom relieve. Corticoids may be also useful in those cases that present with remarkable peritumoral edema and important mass effect. Despite of the advance in therapeutic options, prognosis for patients with melanoma brain metastases remains poor with a median survival time of six months after diagnosis.
authors.affiliation: Neurosurgery Department, Instituto de Neurologia de Curitiba, Jeremias Maciel Perretto Street, 300 Ecoville, Curitiba, PR 81210-310, Brazil.
authors.forename: Carlos R
authors.initials: CR
authors.lastname: Goulart
authors.forename: Tobias Alecio
authors.initials: TA
authors.lastname: Mattei
authors.forename: Ricardo
authors.initials: R
authors.lastname: Ramina
references.citation: Oncology. 2003;64(4):328-35
references.pmid: 12759528
references.citation: Semin Oncol. 2002 Oct;29(5):518-24
references.pmid: 12407517
references.citation: Neuroradiology. 2003 Jan;45(1):44-9
references.pmid: 12525954
references.citation: Cancer Metastasis Rev. 1999;18(3):387-400
references.pmid: 10721492
references.citation: Neurosurgery. 1981 Jan;8(1):26-30
references.pmid: 7207769
references.citation: Eur J Cancer. 2003 Mar;39(4):476-80
references.pmid: 12751378
references.citation: Comput Radiol. 1985 Nov-Dec;9(6):365-72
references.pmid: 4092446
references.citation: Int J Cancer. 2001 Apr 15;92(2):176-80
references.pmid: 11291042
references.citation: J Neurooncol. 1993 May;16(2):173-6
references.pmid: 8289095
references.citation: J Cell Physiol. 1997 Sep;172(3):334-42
references.pmid: 9284953
references.citation: J Neurol Neurosurg Psychiatry. 1989 Jul;52(7):881-6
references.pmid: 2671265
references.citation: Cancer. 1985 Jul 1;56(1):1-9
references.pmid: 4005778
references.citation: Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):858-68
references.pmid: 11849812
references.citation: J Cancer Res Clin Oncol. 2002 Apr;128(4):214-8
references.pmid: 11935312
references.citation: Pathol Oncol Res. 2003;9(3):147-58
references.pmid: 14530807
references.citation: Br J Cancer. 2003 Jan 27;88(2):175-80
references.pmid: 12610499
references.citation: Neurosurgery. 1998 Oct;43(4):834-41
references.pmid: 9766311
references.citation: Melanoma Res. 2003 Feb;13(1):93-6
references.pmid: 12569291
references.citation: J Invest Dermatol. 2001 Aug;117(2):375-8
references.pmid: 11511319
references.citation: Forum (Genova). 2003;13(2):170-82; quiz 190
references.pmid: 14732883
references.citation: Am J Clin Oncol. 1985 Jun;8(3):215-7
references.pmid: 4050740
references.citation: Zentralbl Allg Pathol. 1987;133(2):133-45
references.pmid: 2440200
references.citation: Ann Surg Oncol. 1994 Jan;1(1):38-44
references.pmid: 7834426
references.citation: J Neurooncol. 1992 Feb;12(2):137-40
references.pmid: 1560259
references.citation: No Shinkei Geka. 1978 Jan;6(1):29-37
references.pmid: 628505
references.citation: Am J Clin Oncol. 1990 Oct;13(5):448-51
references.pmid: 1699402
references.citation: Bull Cancer. 1991;78(4):347-53
references.pmid: 1859902
references.citation: Cancer. 1988 May 1;61(9):1926-34
references.pmid: 3355984
references.citation: Wien Klin Wochenschr. 2002 Nov 30;114(21-22):911-6
references.pmid: 12528323
references.citation: Arch Neurol. 1988 Oct;45(10):1126-8
references.pmid: 2845900
references.citation: Radiology. 1987 Oct;165(1):209-13
references.pmid: 3628773
references.citation: J Neurooncol. 1997 May;33(1-2):163-9
references.pmid: 9151233
references.citation: Neurosurgery. 2002 Sep;51(3):656-65; discussion 665-7
references.pmid: 12188943
references.citation: Curr Opin Oncol. 2004 Mar;16(2):161-6
references.pmid: 15075910
references.citation: Acta Oncol. 1998;37(5):463-70
references.pmid: 9831375
references.citation: Hautarzt. 2002 Oct;53(10):659-65
references.pmid: 12297947
references.citation: J Neurooncol. 1993 Apr;16(1):55-9
references.pmid: 8410143
references.citation: Melanoma Res. 1992 Dec;2(5-6):385-91
references.pmid: 1292786
references.citation: Zentralbl Neurochir. 1996;57(1):20-4
references.pmid: 8900895
references.citation: Cancer. 2003 Jan 1;97(1):121-7
references.pmid: 12491513
references.citation: J Neurosurg. 2002 Mar;96(3):544-51
references.pmid: 11883840